You are here

Article Text

Article menu
Download PDFPDF
Adverse drug reactions
Acute interstitial nephritis related to SGLT-2 inhibitor
  1. Alon Bnaya,
  2. Eyal Itzkowitz,
  3. Jawad Atrash,
  4. Mohsen Abu-Alfeilat,
  5. Linda Shavit
  1. Nephrology unit, Shaare Zedek Medical Center, Jerusalem, Israel
  1. Correspondence to Dr Alon Bnaya, Jerusalem, Israel; alonb{at}szmc.org.il

http://dx.doi.org/10.1136/postgradmedj-2020-139490

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are effective antihyperglycemic agents with proven cardiovascular and renal benefits.1 2 The risk for acute kidney injury (AKI) in patients on SGLT-2 inhibitors is considered to be relatively low. However, there have been postmarketing reports of episodes of AKI, some requiring hospitalisation and even dialysis in patients receiving SGLT-2 inhibitors.3 This phenomenon may be related to volume contraction and haemodynamic changes, particularly in patients with other risk factors (such as patients on renin–angiotensin–aldosterone system blocking agents or non-steroidal anti-inflammatory drugs, patients with chronic kidney disease).4 Here, we present a case of acute interstitial nephritis (AIN) and acute tubular necrosis likely related to a SGLT-2 inhibitor.

    A 67-year-old woman was admitted with weakness, dizziness and abdominal pain. Her medical history was remarkable for hypertension, diabetes mellitus, ischaemic heart disease and peripheral vascular disease. Her medications …

    View Full Text

    Footnotes

    • Contributors AB drafted the manuscript. LS, EI, JA and MA-A contributed to the critical revision of the manuscript and final approval of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.